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We identified individuals with variations in ACTL6B, a component of the chromatin remodelingmachinery including the BAF complex.
Ten individuals harbored bi-allelic mutations and presented with global developmental delay, epileptic encephalopathy, and spasticity,
and ten individuals with de novo heterozygous mutations displayed intellectual disability, ambulation deficits, severe language impair-
ment, hypotonia, Rett-like stereotypies, and minor facial dysmorphisms (wide mouth, diastema, bulbous nose). Nine of these ten
unrelated individuals had the identical de novo c.1027G>A (p.Gly343Arg) mutation. Human-derived neurons were generated that recap-
tured ACTL6B expression patterns in development from progenitor cell to post-mitotic neuron, validating the use of this model. Engi-
neered knock-out of ACTL6B in wild-type human neurons resulted in profound deficits in dendrite development, a result recapitulated
in two individuals with different bi-allelic mutations, and reversed on clonal genetic repair or exogenous expression of ACTL6B. Whole-
transcriptome analyses and whole-genomic profiling of the BAF complex in wild-type and bi-allelic mutant ACTL6B neural progenitor
cells and neurons revealed increased genomic binding of the BAF complex in ACTL6B mutants, with corresponding transcriptional
changes in several genes including TPPP and FSCN1, suggesting that altered regulation of some cytoskeletal genes contribute to altered
dendrite development. Assessment of bi-alleic and heterozygous ACTL6B mutations on an ACTL6B knock-out human background
demonstrated that bi-allelic mutations mimic engineered deletion deficits while heterozygous mutations do not, suggesting that the
former are loss of function and the latter are gain of function. These results reveal a role for ACTL6B in neurodevelopment and implicate
another component of chromatin remodeling machinery in brain disease.
Introduction
ACTL6B (MIM: 612458) encodes an actin-related protein
(ARP), which are a class of proteins that resemble actin
and have roles in chromatin remodeling and histone acet-
ylation.1 Though ACTL6B, known as BAF53B, may interact
with multiple complexes in a particular spatiotemporal
order, most investigations have focused on its role in the
BAF (BRG1/BRM-Associated Factor) or SWI/SNF com-
plex,2 which serves as an important regulator of gene
expression by remodeling nucleosomes in an ATP-depen-
dent fashion.3–5 In order to regulate different sets of genes
during development, BAF subunits can be exchanged with
homologous alternatives.3 One such switch in BAF subunit
composition occurs in developing neural cells as they exit
the cell cycle. During this time, the neural progenitor
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specific BAF (npBAF) complex transitions to the neural-
specific BAF (nBAF) complex through the exchange of
several subunits, including BAF53A for its paralog
BAF53B.6 This is partly achieved through increased expres-
sion of miR-9* and miR-124 in post mitotic neurons,
which repress the expression of the gene that encodes
BAF53A, ACTL6A (MIM: 604958).7 nBAF complexes can
bind the transactivator CREST and be recruited to genes
crucial for dendritogenesis through interactions mediated
by BAF53B.8 As a result, loss of BAF53B protein levels dur-
ing neuronal development results in impaired dendritic
outgrowth. An Actl6b knock-out (KO) mouse has previ-
ously been generated and found to have deficits in den-
dritic spine and synapse function, leading to impaired
long-term memory and poor survival.9
While different genes that contribute to the BAF com-
plex have been found to be associated with human disease
(e.g., Nicolaides-Baraitser syndrome [MIM: 601358] and
SMARCA2 [MIM: 600014]; Coffin-Siris syndrome [MIM:
135900] and ARID1B [MIM: 614556]),10,11 ACTL6B has
not been conclusively reported to have a deleterious role
in human neurological diseases. In this study, we identified
individuals with neurodevelopmental disorders with
either inherited recessive mutations or dominantly acting
de novo mutations in ACTL6B and sought to understand
how mutations in ACTL6B might affect the development
of human neurons.
Material and Methods
Description of Studied Individuals
Individuals had whole-exome sequencing as part of local neurode-
velopmental studies on developmental delay and intellectual
disability, autism, or epilepsy (R1, R2a/b, R3a/b, R4, R5, R7, R9,
R10, D2, D3, D7, D8). Informed consent for participating in the
genetic studies was obtained on protocols approved by institu-
tional review boards of local hospitals. Individuals D1 and D4
were enrolled in the DDD study and provided informed consent
for this study. Other individuals had exome sequencing at GeneDx
as part of clinical care (individuals R6, R8a/b, D5, D6, D9), and af-
ter ACTL6B was identified as a candidate gene, provided informed
consent for the sharing of photographs or samples as applicable.
Experimental Procedures for Sequencing
DNA was extracted from peripheral blood from affected individ-
uals and parents using standard protocols. For individuals who
had whole-genome sequencing (R1, R2a/b, R10), the DNA libraries
were prepared by using the Illumina TruSeq DNA PCR-Free kits
using the manufacturer’s protocol. For individuals who had
whole-exome sequencing, the exome libraries were prepared using
Agilent SureSelect kits (R3ab, R4, R6, R8ab, R9, D1, D2, D4-D9),
Roche-NimbleGen EZ exome kits (R5, D3), and Illumina Nextera
kits (R7). More details included in Tables 1 and 2. All libraries
were then sequenced on Illumina HiSeq systems.
Analysis of Sequencing Data
Sequences were aligned using BWA, GATK, Novoalign, Isaac, or
LifeScope software. The variants were called using GATK,
SAMtools, Annovar, CarpeNovo, Isaac, LifeScope, and in-house
pipelines. More details can be found in Tables S1 and S2. After
identification of candidate variants in ACTL6B, their segregation
was confirmed by Sanger sequencing using standard protocols.
Fibroblast Reprogramming to Induced Pluripotent Stem
Cells (iPSCs)
Fibroblasts were obtained from biopsies or from the Coriell Insti-
tute (Table S3) and cultured in DMEM (Invitrogen) supplemented
with 10% bovine serum albumin (Invitrogen). Fibroblasts were
reprogrammed using episomal reprogramming vectors containing
Oct4, Sox2, Myc3/4, Klf4, ShRNA P53 (ALSTEM), and a puromycin
resistance gene using a Neon Transfection System (Invitrogen).
Following transfection, cells were plated on tissue culture plates
coated with Matrigel (Corning) in TesR-E7 media (Stem Cell Tech-
nologies) supplemented with 2 mg/mL puromycin (Sigma). After
48 h of puromycin selection, fresh TesR-E7 media was exchanged,
until distinct and robust iPSC colonies formed, at which point
mTESR1 media (Stem Cell Technologies) was used to maintain
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Table 1. Pathogenic Variants and Key Clinical Information of Individuals with Bi-allelic Mutations in ACTL6B
Individual R1 R2 R3 R4 R5 R6 R7 R8a R8b R9 R10
Inheritance recessive,
homozygous
recessive, compound
heterozygous;
similarly affected
brother passed away
at 5 y
recessive,
homozygous;
similarly
affected brother
passed away
at 4 y
recessive, compound
heterozygous
recessive, compound
heterozygous
recessive, compound
heterozygous
recessive,
homozygous
recessive,
homozygous
recessive,
homozygous;
sister of R8a
recessive, compound
heterozygous
recessive,
homozygous
Coding change
(NM_016188.4)
c.441_443delCTT c.695delC c.1275C>A c.1279del c.389G>A c.556C>T c.852C>G c.740G>A c.1231C>T c.669þ1G>A c.289C>T c.1045G>A c.1045G>A c.724C>T c.617T>C c.1279del
Protein change
(NP_057272.1)
p.Phe147del p.Pro232
Glnfs*24
p.Cys425* p.*427
Aspext*33
p.Arg130Gln p.Gln186* p.Tyr284* p.Trp247* p.Gln411* splicing p.Arg97* p.Gly349Ser p.Gly349Ser p.Gln242* p.Leu206Pro p.*427Aspext*
33
gnomAD MAF 0.00001444, no
homozygotes
absent absent absent 0.000008132,
no
homozygotes
absent absent absent absent absent 0.000004064,
no
homozygotes
0.00001219, no
homozygotes
0.00001219, no
homozygotes
absent absent absent
Age at
assessment
3 y (F) 5 y (M) (passed away
at age 5)
11 m (M)
(passed away
age 5)
8 y (F) 5 m (F) 12 m (M) (passed away
age 2)
4 y (F) 6 y (F) 5 y (F) 14 m (F) 4.5 y (F)
Head circum.
(cm)
43 (3.5 SD) NA 44 (3rd) 50.3 (10th %ile) 38.4 (3.0 SD) 42 (2.4 SD) normal 41.5 (3.8 SD)
at 18 m
39 (7th %ile) at
4 m
43 (2.5 SD) 47 (2.8 SD)
ID, DD þ, severe þ þ þ, severe þ, severe þ, severe þ, severe þ, severe þ, severe þ, severe þ
Speech   NA  NA  NA    
Ambulation   NA  NA  NA    þ, with support
Axial
hypotonia
þ þ þ þ þ þ þ þ þ þ þ
Limb spasticity þ þ þ þ þ þ þ þ þ þ þ
Feeding
difficulties
þ þ þ  þ þ þ þ þ þ 
Epilepsy þ þ þ þ þ þ þ þ þ þ þ
Seizures (age at
beginning)
3 m 3 y NA NA 2 m neonatal (25 days) infancy infancy infancy antenatal 9 m, infantile
spasms
Seizure types myoclonias
2–6 per day
complex partial NA NA tonic and myoclonic focal onset epilepsy,
progressed to infantile
spasms
NA NA NA myoclonic and tonic
seizures
tonic and
myoclonic
(Continued on next page)
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and proliferate the colonies. Quality control experiments for iPSCs
include mycoplasma testing, short tandem repeat profiling to
ensure no sample mix-ups, assessment of endogenous pluripo-
tency factor, immunocytochemistry for pluripotency markers,
and molecular karyotyping.
Molecular Karyotyping
To ensure no chromosomal abnormalities occurred as a result of
iPSC induction or gene editing, DNA from all generated iPSC lines
was sent to Prince of Wales Hospital (Shatin, Hong Kong) for
sequencing on an Ion Torrent Hi-Q Sequencer (Thermofisher).
Samples were sequenced with an average of 4 million 150 bp reads
per sample, for an average coverage of 0.00143. Analysis was pre-
formed using CNV-Seq.12 Positive controls included cells of origin
and cells from families with first-degree relationships where we
could detect Mendelian inheritance of CNVs > 1 Mb.
Differentiation of iPSCs to Forebrain Neural Progenitor
Cells (NPCs)
iPSCs were differentiated to forebrain NPCs according to our
previously described methods.13,14 iPSC colonies were dissociated
and resuspended in DMEM/F12media supplemented with N2 (Invi-
trogen) B27 (Invitrogen) and BSA (1 mg/mL), Y27632 (10 mM;
AdooQ Bioscience), SB431542 (10 mM; Selleckchem), and Noggin
(200 ng/mL;GenScript) onto non-adherent plates to formorganoids.
After 1 week of maintenance as organoids, cells were dissociated and
plated on Matrigel-coated plates in DMEM/F12 supplemented with
B27, bFGF (20 ng/mL), EGF (20 ng/mL), and laminin (1 mg/mL) for
a further 7 days of differentiation, with media exchanged every
3 days. Cells were assessed for NPC morphology and stained for
markers of forebrain NPCs (PAX6, SOX2, TUJ1) and OCT4.
Differentiation of NPCs to Post-mitotic Neurons
For short-term (5 days) differentiation, NPCs were plated in
DMEM/F12 media supplemented solely with B27. If longer-term
(>5 days) differentiation was required, NPCs were plated in
BrainPhys SM1 (Stem Cell Technologies) and N2-A supplemented
media (StemCell Technologies). 50% of this media was exchanged
every 3 days. Previous work has shown that neurons generated
using this methodology express both GABAergic (30%) and
glutamatergic (60%) markers14 and are negative for midbrain
markers, such as tyrosine hydroxylase. Approximately 5%–10%
of cells stain for GFAP, an astrocyte marker.
Whole-Cell Recordings
For whole-cell patch-clamp recordings, individual coverslips con-
taining differentiated hIPSC-derived neurons were transferred
into a heated recording chamber and continuously perfused
(1 mL/min) with BrainPhys Neuronal Medium (Catalog # 05791;
StemCell Technologies) bubbled with a mixture of CO2 (5%) and
O2 (95%) andmaintained at 25
C.Whole-cell patch clamp record-
ings were obtained using borosilicate pipettes (3–6MU), filled with
intracellular solution that contained the following (in mM):
5 HEPES, 2 KCl, 136 potassium gluconate, 5 EGTA, 5Mg-ATP, 8 cre-
atine phosphate, and 0.35 GTP. The pH was adjusted to 7.27 with
KOH, and the osmolarity adjusted with distilled water or concen-
trated potassium gluconate if needed to between 295 and 298
mOsm with an osmometer (3320; Advanced Instruments). After a
recording was completed, the nominal membrane potential in
voltage- and current-clamp recordings was corrected for the calcu-
lated 10mV liquid junction potential. All potential values reportedT
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Table 2. Pathogenic Variants and Key Clinical Information of Individuals with De Novo Mutations in ACTL6B
Individual D1 D2 D3 D4 D5 D6 D7 D8 D9 D10
Coding change
(NM_016188.4)
c.1027G>A c.1027G>A c.1027G>A c.1027G>A c.1027G>A c.1027G>A c.1027G>A c.1027G>A c.230A>G c.1027G>C
Protein change
(NP_057272.1)
p.Gly343Arg p.Gly343Arg p.Gly343Arg p.Gly343Arg p.Gly343Arg p.Gly343Arg p.Gly343Arg p.Gly343Arg p.Asp77Gly p.Gly343Arg
gnomAD MAF absent absent absent absent absent absent absent absent absent absent
Age at assessment 5 y 6 m (M) 29 y (F) 6 y 6 m (M) 5 y 9 m (F) 4 y 6 m (F) 3 y (F) 21 y (F) 2 y 6 m (F) 8 y (F) 12 y (F)
Head circum. (cm) 49 (2.1 SD) 53 (11th %ile) 51 at age 5 year
(50th %ile)
48.6 (2.2 SD) 48 (2nd %ile) 48.0 (20th %ile) 52.2 (2.0 SD) 45.5 (0.1 SD) 50th–75th %ile 52 (1, 2 SD)
Degree of ID/DD severe severe severe severe severe severe severe severe severe severe
Speech    10–20 words,
receptive skills
better
 ; gestures   ; gestures;
receptive skills
better
one word
Ambulation  þ limited delayed; wide-
based gait
    NA delayed; wide-
based gait
Hypotonia NA þ þ NA þ þ NA - NA þ
Autism spectrum
disorder
NA þ unknown þ NA NA NA  þ 
Features of ASD NA NA þ NA stereotypies NA handwringing  NA stereotypies
Seizure disorder       Infantile spasms
and GTCS
 NA 
MRI NA NA NA NA NA thinning of the
corpus callosum
Generalized
atrophy at 2y
mild
periventricular
gliosis
NA Nl
Wide or
prominent
forehead
þ þ þ þ   þ þ þ 
Hypertelorism þ þ þ   þ  þ þ 
Wide mouth þ þ þ    þ þ NA þ
Short phalanges or
nails
NA þ  þ   þ  þ 
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reflect this correction. Once whole-cell recording had been estab-
lished, neurons were routinely held in voltage clamp at 70 mV
except when examining changes in the resting membrane poten-
tial and rheobase, which was performed in current clamp. Cells
were studied only if they exhibited a stable holding current and
access resistance for at least 10min before experimental manipula-
tions. Data were acquired using a Digidata 1550A/ Multiclamp
700B (Axon Instruments) and Clampex 10.5 (Molecular Devices).
Currents were filtered at 2 kHz and digitized at 20 kHz.
CRISPR/Cas9 Gene Editing
A double nickase CRISPR/Cas9 gene editing system with a Paprika
RFP (pRFP) reporter and gRNA targeting the first exon of the
ACTL6Bwas used for KO experiments. For ACTL6Bext33 repair ex-
periments, a wild-type CRISPR/CAS9-pRFP gene editing system
was used to target the mutation in the stop codon of exon 14 of
ACTL6B. 1 mg of construct was added per transfection reaction,
and transfection was carried out simultaneously with iPSC induc-
tion to ensure clonality, as previously described.14 After transfec-
tion, cells were selected for puromycin resistance and RFP visuali-
zation as described8 allowing for cell expansion from a single
edited fibroblast. Potentially edited colonies were expanded and
stored as cell lines after which DNA was extracted and Sanger
sequenced at Genome Quebec.
RNA Sequencing
RNA samples with RIN values > 9.0 were submitted to Genome
Quebec for RNA sequencing. Eight libraries were run per lane of an
Illumina HiSeqV4 2500 flow cell (125 bp paired-end reads), which
achievedanaverageof40millionreadsper library.Forbioinformatic
processing, we used FASTX-Toolkit, TopHat15 Bowtie2,16 and Cuf-
flinks217 with default parameters to preprocess, align, and assemble
reads into transcripts, estimate abundance, and test differential
expression. More detailed methods can be found in Chen et al.18
Western Blot
Cells were lysed with RIPA buffer (Sigma) supplemented with
SIGMAFAST Protease Inhibitor Tablets (Millipore-Sigma). Protein
concentrations were determined using a Pierce BCA Protein Assay
Kit (ThermoFisher). Approximately 15 mg of protein was loaded
per well in Mini-PROTEAN TGX Stain-Free Precast Gels (Biorad).
Gels were run at 150V for approximately 75 min, and then trans-
ferred to a nitrocellulose membrane using a Trans-Blot Turbo
Transfer System (Biorad). Membranes were blocked in 4% non-
fat milk dissolved in TBS-T buffer (tris-buffered saline-tritonX;
Sigma-Aldrich) for 20 min and then incubated with primary anti-
bodies overnight at 4C with shaking. Blots were washed three
times in TBS-T for 5 min and then incubated with appropriate
mouse or rabbit secondary antibodies for 1 hour at room temper-
ature. Blots were washed a further three times in TBST for 5 min,
then imaged using a ChemiDoc XRSþ System (Biorad). Blots
were imaged and analyzed using ImageLab (Biorad) software,
and statistical analysis was preformed using Student’s t tests
when two samples conditions were present and a one-way
ANOVA when more than two sample conditions were present.
Blots were normalized to b-actin. Further details on the antibodies
used for WB can be found in Table S5.
Quantitative PCR
Reverse transcriptions were done on the total RNA fraction in or-
der to obtain cDNA in 40 mL volume containing 1 mg of total
RNA, 0.5 mg random primers, 0.5 mM dNTPs, 0.01 M DTT, and
400 U M-MLV RT (Invitrogen). The reactions were performed in
a total volume of 20 mL on a 384-well plate either using
an Applied Biosystems 7900 HT (Applied Biosystems) or a
QuantStudio 6 (Thermofisher) PCR Machines. For each well,
PCR mix included 10 mL of Power SybrGreen PCR Mastermix
(Life Technologies), 1 mL of primers/probe mix, 2 mL of cDNA,
H20 up to 20 mL. Serial dilutions of a mix of cDNA ranging be-
tween 0.003052 ng and 50 ng were used to generate a calibration
curve for an absolute quantification. Protein levels were given as a
ratio between the relative quantities of the gene of interest and
the endogenous control. GAPDH was used as internal control
for normalization. The normalized expression levels were then
compared between cell lines using either a Student’s t test or an
ANOVA with post hoc t test. Further details on the primers used
for qPCR can be found in Table S6.
Immunofluorescence
Adherent cells were washed with PBS, then fixed with 3% parafor-
maldehyde (Sigma-Aldrich) on slides for 15 min. Samples were
permeabilized with 0.5% TX-100 (Sigma-Aldrich) in 0.5% PBS-
BSA for 15 min, and then blocked in 0.5% PBS-BSA for an
additional 15 min. Primary antibodies were added in appropriate
dilutions (Table S5) in 0.5% PBS-BSA and added to samples for
30 min. Samples were washed in 0.5% PBS-BSA containing an
appropriate dilution of secondary antibody (Table S5) was added
to the samples and incubated for 30 min in the dark. Samples
were washed with 0.5% PBS-BSA. Samples were then visualized
on an Apotome Florescent microscope (Zeiss). Neurolucida
Tracing Software (MBF Bioscience) was used to measure nuclei sur-
face area, soma surface area, and projection length. Images were
processed and scale bars added in ImageJ.
Chromatin Immunoprecipitation (ChIP) Sequencing
Samples were prepared for ChIP-Seq and ChIP-qPCR using a
Magna ChIP-Seq kit (Millipore-Sigma). Cells were cross-linked at
day 0 and day 5 of differentiation by immersion in 37% formalde-
hyde. Glycine was added at a final concentration of 125 mM to the
samples to inactivate cross-linking. DNAwas sheared using a S220
Sonicator (Covaris) and precleared using a protein A or G agarose
beads. All samples were then probed using both a mouse mono-
clonal (Santa Cruz, sc-17796) and rabbit polyclonal (Santa Cruz,
sc-10768) antibody directed against BRG1 overnight at 4C. An
IGG control was ran for both rabbit polyclonal and mouse mono-
clonal antibodies using a pooled sample composed of equal parts
of all samples used for ChIP. A 0.2 M glycine solution (pH 2.6)
was used for elution of cross-linked proteins and DNA from the
beads. DNAwas purified using Agencourt AMPure XP Beads (Beck-
man Coulter). Libraries were constructed using an NGS Library
Preparation Kit (Millipore-Sigma) and sent to Genome Quebec,
where they were sequenced using an Illumina HiSeqV4 2500
flow cell (125 bp paired-end reads) with between 11 and 12 sam-
ples sequenced per lane.
ChIP-Seq Analysis
Quality Trimming and Pre-processing
Sequencing adaptors were clipped using Trim Galore. Quality
trimming was done with same tool. A phred score cut-off value
of 20 was used. Reads shorter than 20 bp were filtered out. Reads
were aligned to the Human Reference Genome (hg19) using
BWA software v.0.7.10. Resulting bam files were filtered for
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minimal mapping quality (MAPQ R 20) and all alignments
with samflag 4 (read unmapped) were excluded using
SAMtools (v.0.1.19). Duplicates reads were removed using the
MarkDuplicates module of Picard (v.1.141) with the option RE-
MOVE_DUPLICATES ¼ true.
Peak Calling
The identification of ChIP-seq enriched regions (peaks) was
performed using MACS2 (v.2.1.1); (macs2 callpeak –format
BAM –broad –nomodel -q 0.05 –broad-cutoff 0.1 –extsize 500).
Differential binding-sites analysis were done using the DiffBind
Bioconductor R package (v.2.6.6). Diffbind calls some of the
DESeq2 (v.1.18.1) functions to perform the contrast analysis be-
tween pairwise p.*427Aspext*33 or control D5 versus D0 groups
(dba.analyze (method ¼ DBA_DESEQ2)). For each comparison,
DiffBind generated a set of consensus peaks with the require-
ment that peaks must be in at least two of the samples
(minOverlap ¼ 2). Standardized differential analysis was then
performed using the following default settings for dba.analyze:
method ¼ DBA_DESEQ2, FDR % 0.05, bSubControl parameter
set to TRUE, bFullLibrarySize set to TRUE. Thus, raw number
of reads in the control sample was subtracted and the library
size was computed for each sample and used for the normaliza-
tion. sizeFactors is called with the number of reads in the BAM
files for each ChIP sample, divided by the minimum of these.
The final normalized counts returned are the raw reads
(adjusted for control reads) divided by the normalization factors
(result of calling sizeFactors()). Significantly different peaks were
then annotated with HOMER (v.4.7) using RefSeq annotations
(distal_distance ¼ 10000, distance5d_lower ¼ 10000, distan-
ce5d_upper ¼ 100000, gene_desert_size ¼ 100000, proximal_
distance ¼ 2000).
Results
Identification of French-Canadian Families with
Homozygous Mutations in ACTL6B
By exome sequencing of families with neurodevelopmen-
tal disorders in Quebec, we identified a family with
two children with a homozygous mutation in ACTL6B
that eliminates the stop codon (c.1279del, GenBank:
NM_016188.4) and extends the reading frame by an
additional 33 amino acids (p.*427Aspext*33; GenBank:
NP_057272.1; individual R3; Figure 1, Tables 1 and S1).
Sequencing both affected children, their unaffected
older brother, and both parents from family R3 revealed
that c.1279del was the only mutation identified in the
family that was protein altering, followed an autosomal-
recessive inheritance model, and was absent from all
genomic databases. Both parents and the unaffected
brother were carriers, and all are healthy. The phenotype
of the disorder is severe: both brothers died early in life
(4 and 6 years) of aspiration asphyxiation, were non-ver-
bal, non-ambulatory, and required 24-h care for all needs.
Parents reported incessant crying (10þ h per day), seizures
beginning at 3 months, and sleep difficulties (Table 1). An
MRI of the brain was provided and had no indications
from the reviewing radiologist. Careful tracing of the line-
age of family R3 using Catholic Church records7 revealed a
common ancestor, which we determined to be the most
likely origin of the mutation in family R3 (Figure S1A
and Supplemental Material and Methods). We genotyped
five other members from family R3 across four generations
and could identify appropriate inheritance of themutation
from the predicted founder (Figure S1B). The R3 parents of
the proband can be traced to a brother and sister going
back six generations in the mother and five generations
in the father, an event unknown to the R3 parents prior
to birth of the probands (Figure S1B).
Another French-Canadian family (defined as both great-
grandparents being born in the province of Quebec, Can-
ada) with child R10 (Table 1) also had this same mutation
with almost identical phenotype, suggesting that this mu-
tation is not private to the R3 family but rather may be a
specific but rare variant in the French-Canadian popula-
tion. We assume that families R3 and R10 are distantly
related but could not identify the branch point at which
the pedigrees may overlap.
Bi-allelic Mutations in ACTL6B Cause a Severe
Neurodevelopmental Disorder
We were able to identify eight additional families with a
similar phenotype (Tables 1 and S1) with bi-allelic muta-
tions. A majority of these identified mutations resulted in
premature termination codons and were located in highly
conserved sequences (Figures 1B and 1C). We considered it
very likely that most of these mutation sites resulted in
nonsense-mediated decay (NMD) of the transcript, as
they occur well in advance of the penultimate exon,19
and strongly suggests that the disease is due to loss of func-
tion of ACTL6B. However, some mutations including the
c.1279del mutation were located in the final exon of
ACTL6B (Figure 1B) and were therefore not predicted to
lead to NMD.19 Heterozygous stop mutations are present
in healthy parents, suggesting a recessive disorder. Selected
case vignettes can be found in the Supplemental Note.
De Novo Missense Mutations at Specific Loci in ATCL6B
Cause a Different, Severe Neurodevelopmental Disorder
Over the course of identifying subjects with mutations in
ACTL6B, we found ten individuals with heterozygous de
novo missense mutations in ACTL6B with hypotonia,
intellectual disability, developmental delay, autism, and
Rett-like stereotypies such as handwringing (Figure 1,
Tables 2 and S2). Detailed case vignettes of some subjects
are presented in the Supplemental Note. This was
surprising, given that we observed heterozygous stop/
frameshift mutations in healthy individuals arguing for a
recessive inheritance model. Nine of ten of these individ-
uals possess the same well-conserved c.1027G>Amutation
(p.Gly343Arg) (Figure 1C and Table 2). p.Gly343Arg
(GenBank: NM_016188.4; hg19: chr7: 100244258; exon
12) is not seen in the 60,706 ExAC subjects. The same
holds true for the other observed variant, p.Asp77Gly
(GenBank: NM_016188.4; hg19: chr7: 100253082; exon
3), both of which are likely gain-of-function mutations
since heterozygous stop mutation carriers have no disease.
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3D modeling of the de novo dominant and the recessive bi-
allelic mutations (Figure 1D) shows no spatial clustering of
mutation sites. BAF53B has an actin-related domain,
which is subdivided into four subdomains.20 Subdomains
I and III are structural and also contain residues that
interact with ATP.21 Subdomain II is the smallest domain
and enables the protein to have polar and non-polar orien-
tations. Previous work has shown that mutations in this
subdomain impair dendritic outgrowth.4 Subdomain IV
interacts with subdomain 120 and is necessary for the
interaction of the protein with actin.21 We mapped these
subdomains onto a model of BAF53B derived from
S. cervisiae; ARP4 structure and found that the variants
occurred in all subdomains. Specifically, p.Phe147del,
p.Cys425, p.Arg130Gln, and p.Gln411* variants occur in
subdomain I, the p.Asp77Gly variant occurred in subdo-
main II, p.Gly343Arg, p.Gly349Ser, and p.Arg130Gln
occur in subdomain III, and p.Gly425* occurs in subdo-
main IV (Tables 1 and 2). We did not find any concentra-
tion of mutations in a particular domain.
Two other BAFopathies, Nicolaides-Baraitser syndrome
(MIM: 600014) and Coffin-Siris syndrome (MIM:
614556), so called because they affect genes that code for
proteins that can be incorporated into the BAF complex,
have sparse scalp hair and coarse facial features, though
this is a wide spectrum in affected individuals. We ob-
tained images of several probands in this study and did
not observe coarse features in the majority of subjects
Figure 1. Location of Mutations in ACTL6B Found in Individuals with Potential Recessive or Dominant Disease-Causing Mutations
(A) Photos of individuals with ACTL6B mutations. Note broad mouth of individuals D1, D2, D3, and D7, diastema in D1, D3, D7,
bulbous tip of the nose in all D individuals, and hypertelorism with telecanthi in individual D8. Lower right: MRI images of individuals
with recessive ACTL6B mutations. For individual R4, note white matter T2 hyperintensity (arrows). For individual R8, note enlarged
lateral ventricles and asymmetric gyral pattern (left, arrows). On the right, note thin corpus callosum (arrows).
(B) Linear graph of mutations in ACTL6B (introns not drawn to scale).
(C) Conservation of the residues affected by amino acid substitutions.
(D) 3D model generated with SWISSMODEL based on S. cerevisiae Arp4 (yeast homolog of ACTL6B), visualized with Swiss-PdbViewer
showing that recessive mutations are not focused in one region. Note, however, that the dominant mutations seem to lie at the periph-
ery of the protein and thus they might affect protein-protein interactions.
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(Figure 1A). However, in individuals with the dominant
mutations, we did find common features such as a wide
mouth, diastema, and bulbous tip of the nose. In the
case of MRI brain structure, this was grossly normal, with
subtle but not specific features (common across many
MRI scans of children with neurodevelopmental diseases)
detected for some individuals (Tables S1 and S2).
Modeling the p.*427Aspext*33 Variant in Human
Neurons
Human stem cells are a powerful model for functional
genetic studies as mutations can be assayed on a relevant
genetic background and are amenable to genetic engi-
neering. All iPSC lines generated in this study had
normal chromosomal integrity, presented typical hall-
marks of pluripotency (Figure 2A), including expression
of endogenous pluripotency genes (Figures S2A and
S2B), and had the capacity to differentiate into all three
germ layers (Figure S2C). iPSCs were utilized to generate
forebrain neural progenitor cells (NPCs), which ex-
pressed neural- and forebrain-specific markers (Figures
2B and S3). Mature neurons generated from wild-type
cells expressed markers of cortical neurons and displayed
electrophysiological characteristics typical of high-qual-
ity iPSC-derived neurons, including spontaneous action
potentials and excitatory post-synaptic currents (Figures
2D–2F).
To assess the validity of iPSC-derived neurons to model
ACTL6B mutation syndrome, we sought to recapitulate
the developmental expression increase2 in ACTL6B in
wild-type neurons, where ACTL6B expression is absent
from dividing cells but is present in post-mitotic cells.2
Figure 2. Generation of iPSC-Derived
Neurons for BAF53 Studies
(A) Representative images of quality control
staining done on iPSCs.
(B) Representative quality control staining
on NPC cultures.
(C) Representative staining of control cells
for TUJ1 and MAP2 at D15 of differentia-
tion.
(D) Representative trace of miniature EPSCs
from D25 neurons held at 40 mv.
(E) Representative recordings showing
spontaneous activity of D25 neurons in cur-
rent-clamp mode.
(F) Trace of a hyperpolarizing pulse showing
a depolarizing sag followed by multiple
rebound action potentials. The first action
potential is shown at a higher temporal res-
olution.
All scale bars represent 40 mm.
We found that ACTL6B increased in
expression from day 1 to day 5. To
minimize time in culture (which can
increase experimental variation), we
selected 5 days differentiation as our
time point for post-mitotic transcrip-
tomic analysis, where we could be confident ACTL6B
would be well expressed (Figures 3A and 3B). To charac-
terize the basic expression pattern of key genes involved
in the BAF complex in both p.*427Aspext*33 and control
cells, we assessed the expression of ACTL6B, ACTL6A,
and SMARCA4 (MIM: 603254), a core DNA binding
component of the BAF complex. Genes were assessed at
day 0 (D0) and day 5 (D5) of differentiation. ACTL6B
expression increased significantly in both p.*427Aspext*
33 and control cells as cells differentiated. We also detected
a significant decrease of ACTL6B in p.*427Aspext*33
compared to control cells at D5 (Figure 3C). ACTL6A had
high expression in proliferating cells with a significant
decrease after 5 days, yet was still clearly expressed at day
5 in both control and p.*427Aspext*33 cells (Figure 3C).
We detected no significant difference in the expression
level of SMARCA4 between any cell line or time point
(Figure 3C). To confirm and validate these mRNA-based
data, we performed western blot on protein extracted
from p.*427Aspext*33 and control cells at proliferative
and post-mitotic time points (Figure 3D). These data sug-
gest that there is no difference in protein level of any of
BAF53A, BAF53B, and BRG1 between control and p.*
427Aspext*33 cells. By developmental period (prolifer-
ating and post-mitotic), we observe consistent protein
levels of BAF53A and BRG1 and absent BAF53B in prolifer-
ating cells.
Engineered Homozygous Deletion of ACTL6B in Human
Neurons Causes Severe Loss of Dendrites
What is the function of ACTL6B in developing human
cells and what is its role in human disease? Our previous
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experiments suggest that BAF53B is specific to post-mitotic
cells, as reported in rodents,22 so we opted to inactivate
ACTL6B to determine cellular phenotypes resulting from
complete gene loss.
We knocked out ACTL6B from control human cells
using a clonal genetic engineering technique23 (Supple-
mental Material and Methods). We generated two inde-
pendent ACTL6B knockout cell lines that had different ho-
mozygous frameshift mutations in exon 1 (KO1 and KO2;
referred to collectively as KO) and compared them to the
isogenic cell line that had undergone no editing event
(control) (Figures 4A and 4B). The use of two indepen-
dently edited cell lines with the same outcome (homozy-
gous loss of ACTL6B) is one way to protect againstcell
line artifacts, where we do not expect the same artifact to
be present in both cell lines. To further ensure this, we
Sanger sequenced the five genomic regions most likely to
be edited by the gRNAs used, all of which were unedited,
suggesting no off-target effects, as has been reported and
systematically assessed previously.24 We also performed
long-range (1.6 kb) sequencing to ensure that these
mutations were in fact homozygous and not due to a large
deletion in one allele, in addition to DNA-based qPCR to
confirm equal gene dosage between edited and unedited
lines (Supplemental Material and Methods). After clonal
gene editing and careful genomic integrity assessment,
we planned to investigate dendritic length anomalies in
a more mature neuronal state, since mouse KO Actl6b neu-
rons show deficits in dendrite development.4 To do this,
we differentiated human ACTL6B KO cell lines and their
matched isogenic controls for 15 days (D15, a time point
where we routinely see extensive neuronal arborization
in culture23) and confirmed the loss of ACTL6B expression
at the mRNA and protein level (Figures 4C and 4D). We
used MAP2 and TUJ1 as dendritic and neuronal markers,
respectively, since these are routinely used in neuroscience
research for this purpose.25,26 We observed virtually no
MAP2 staining in ACTL6B KO cells, while MAP2 was
clearly present in most cells in the isogenic controls
(Figure 4E). We also observed a larger nuclear size in the
deleted cells, as assayed by DAPI, an effect that is obvious
on cell examination (Figure 4F).
The p.*427Aspext*33 Alteration Phenocopies ACTL6B
KO Dendritic Deficits and Is Reversible upon Bi-allelic
Genetic Repair
From our genotype-phenotype data from affected individ-
uals and their first-degree relatives, we reasoned that
recessive mutations cause a loss of function of ACTL6B
and thus may mimic the cellular phenotype of the
engineered ACTL6B KO cells. To demonstrate this, we
reasoned that using these cell lines and comparing them
to a clonally repaired version should provide interpretable
data.
We bi-allelically repaired the ACTL6Bext33 line to a
wild-type genotype and simultaneously reprogrammed
these edited cell lines, where we had several unsuccessful
repairs that could be used as isogenic controls. Homol-
ogy-directed repair was performed using a wild-type tem-
plate in p.*427Aspext*33 fibroblasts plated at low density
and iPSCs colonies derived from a single fibroblast were
isolated, ensuring clonality and purity of repair.23 After
Figure 3. Comparison of Control and ACTL6Bext*33 before and after Expression of ACTL6B
(A) Diagram illustrating the production of control and ACTL6Bext*33 iPSC-derived NPCs from fibroblasts.
(B) ACTL6B expression normalized to GAPDH expression plotted against number of days of differentiation of NPCs. n ¼ 4, error bars
represent standard error around the mean.
(C) Expression of key genes in the SWI/SWF complex in 706 ACTL6Bext*33 and control NPCs in proliferating and post-mitotic states.
Genes are normalized to GAPDH expression. nR 3; Student’s t test, *p < 0.05, **p < 0.01.
(D) Western blots assessing the level of proteins encoded by the genes displayed in (C).
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iPSC expansion of many colonies, we extracted DNA and
Sanger-sequenced around the mutation site (Supplemental
Material and Methods, sections S2–S4). A colony with
c.1279del mutation repaired to a wild-type genotype was
identified and labeled as successful repair (SR) and differen-
tiated to NPCs in tandem with an unsuccessful repair (UR)
line, which was derived from a colony that received the
CRISPR complex and repair template but where no editing
event occurred (Figures 5A and 5B).We differentiated these
cells from NPCs to D15 neurons and then stained for
MAP2 and TUJ1, identical in design to the KO study. As
shown in Figures 5D and 5E, affected individual cells reca-
pitulate the loss of MAP2 and increased nuclei size
observed in the KO, a result that is reversed on repair of
the homozygous base change in ACTL6B. The similar
cellular phenotype between affected individual and engi-
neered KO neurons suggest that the ACTL6Bext33 reces-
sive mutation causes similar deficits to the complete KO
and thus could be interpreted as causing a loss of function.
Loss of Dendrites due to Loss of Function of ACTL6B Is
Likely due to Delayed Maturation of Young Neurons
Is the observed decrease inMAP2 staining due to immature
differentiation, differential differentiation, or a specific
deficit in dendrite development? To try to address these
questions, we first asked whether the cell types in each
condition were equivalent. To investigate this question,
we stained D15 cultures from repaired and KO cells and
their control with an astrocyte (GFAP) and a neuronal
marker (TUJ1), with the hypothesis that perhaps deficits
in ACTL6B bias NPCs toward becoming astrocytes.
Figure S4A shows the results of this experiment; we could
not detect different numbers of cells that stained for
GFAP. We include in this experiment a positive control
where we add 0.1% BSA which can glialize cell cultures.
To support the idea that deficits of ACTL6B do not lead
cell cultures to become more glial and to provide more
specificity than just GFAP, we assessed the transcriptomic
data of p.*427Aspext*33 and control cells we had gener-
ated in an RNA-seq experiment. We found no consistent
pattern in mRNA expression levels of glial markers
ALDH1L1, GFAP, and GJA1 and neuronal markers RBFOX3
and TUBB3 to suggest an increase in expression of glial-
related genes in ACTL6Bext33 cells compared to control
cells (Figure S4B). These data indicate that deficits in
ACTL6B do not lead NPCs to become more astrocytic.
We therefore ruled out the loss of MAP2 staining being
due to cells being pushed toward an astrocytic fate.
As a simple measurement of differentiation, we opted
to photograph control, ACTL6Bext.33, ACTL6B KO, and
Figure 4. Generation and Characterization of ACTL6B KO Neurons Reveals a Loss of Dendrites
(A) Diagram of the experimental approach taken to generate ACTL6B KO NPCs.
(B) Sanger sequencing traces of two ACTL6B KO lines.
(C) ACTL6B expression in control and ACTL6B KO NPCs at a D0 and D5 time point (n R 3).
(D) Western blots assessing the protein levels of BAF53A/B in ACTL6B KO lines.
(E) Representative TUJ1 and MAP2 staining of control and ACTL6B KO D15 immature forebrain neurons.
(F) Quantification of the surface area of the nucleus in the cell lines shown in (E) (n > 50).
Student’s t test, *p < 0.05, **p < 0.01.
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repair cells across several developmental time points.
Figure S5 shows that in contrast to repaired and control
cell lines, unrepaired and KO ACTL6B cells are not
branched prior to day 20, whereas at day 25 through day
50, all lines show branching.
These data suggest that deficits in ACTL6B lead to a delay
in differentiation in early post-mitotic states. This delay in
differentiation, if true in vivo, may lead to cell connectivity
deficits.
The p.*427Aspext*33 Variation Alters BRG1 Genomic
Binding and Affects Gene Expression
This project began with the index case subject R3 (p.*
427Aspext*33), who had fibroblasts collected prior to mu-
tation identification, so our study is heavily biased toward
this case. To this end, we opted to continue experiments
with these cells, with the idea that we might recruit cells
from other subjects or design exogenous templates for vali-
dation studies.
We wanted to understand the molecular consequences
of the p.*427Aspext*33 variant and how this might lead
to neurodevelopmental deficits. Due to a lack of ChIP
grade antibodies directed specifically to BAF53B, we
chose to perform a ChIP-seq experiment targeting
BRG1, a key subunit of the BAF complex with ATPase ac-
tivity that is found in both BAF53B- and BAF53A-
containing BAF complexes.11 We chose the D0 and D5
time points for proliferating and post-mitotic cells,
respectively, and performed ChIP in control and
ACTL6Bext33 cells using eight replicates per subject per
time period (32 ChIP experiments). We performed
several QC experiments with different anti-BRG1 anti-
bodies prior to sequencing to ensure appropriate param-
eters (not shown) and chose two antibodies to provide
overlapping datasets of Brg1-containing BAF complex
binding (Figure 6A). After sequencing and QC, we
analyzed differential binding in D5 cells to understand
how the genomic targeting of Brg1-containing BAF com-
plexes may be altered by a mutant BAF53B subunit. ChIP
peaks were called in at least 2/8 lines, and differential
analysis used reads from all replicates within the peak.
10,222 peaks were common across all data points
(Figure 6B), suggesting that BRG1 remains mostly at
the same location in the genome, even in mutant
ACTL6B cells and irrespective of developmental state.
We focused our primary analysis on D5, since this is
when ACTL6B is expressed, and tried to determine
whether there was differential binding of BRG1 at peaks
called in both p.*427Aspext*33 and control cells. Using
FDR < 0.05, we found no significant differences; however,
using an uncorrected p value of 0.05 revealed 382 common
genomic regions that were significantly differentially
bound and every one of these showed increased binding
in affected individual cells (Figure 6C). Loss of function
Figure 5. Repair of the ACTL6B c.1279del Mutation Restores Morphological and Dendritic Deficits
(A) Schematic detailing ACTL6B CRISPR repair.
(B) Sanger sequencing traces of a successful repair (SR) and unrepaired (UR) cell line generated from ACTL6Bext*33 cell line.
(C) ACTL6B expression in SR and UR NPCs at a D5 time point (n ¼ 6).
(D) Representative TUJ1 and MAP2 staining taken from SR and UR forebrain immature neurons at D15. Scale bars represent 40 mm.
(E) Quantification of the surface area of the nucleus and soma and the length of projections in the cell lines shown in (D) (n > 50).
Student’s t test, *p < 0.05, **p < 0.01, ***p < 0.001.
826 The American Journal of Human Genetics 104, 815–834, May 2, 2019
of BAF53B may lead to increased affinity or stabilization of
the BAF complex to its genomic targets, possibly through
retention of BAF53A. More than half of the 382 sites that
BRG1-containing BAF complexes bound to were associated
with genes (Figure 6C). PANTHER GO terms associated
with the differentially bound regions were related to cell
adhesion and neurodevelopment (Figure 6D). This list
included autism-associated genes AUTS2, PTEN, FOXP2,
and SMARCA2.
To further assess whether mutant ACTL6B leads to
increased binding of BAF to genomic regions, we per-
formed a within-subjects analysis in proliferating (D0)
and differentiating (D5) cells, looking for peaks present at
both developmental stages using FDR < 0.05 for peak call-
ing. While we did not find the same peaks that were called
between case subjects and control subjects (suggesting the
experiment was underpowered since we used eight repli-
cates in each block), we found evidence for a general
decrease in BRG1 binding in differentiated cells compared
to proliferating cells in those genomic regions present at
both D0 and D5 in control conditions, in contrast to
the p.*427Aspext*33 cells where there was a consistent
Figure 6. ACTL6Bext*33 Variant Leads to Increased Binding of BRG1-BAF Complex to the Genome
(A) Diagram illustrating the ChIP-seq experiment.
(B) Venn diagram showing overlap of genes that the BRG1 complex is bound to.
(C) Decreased binding at all 382 FDR significant sites in control cells compared to ACTL6Bext*33 cells (pink dots are significant, while
blue dots are not).
(D) Proportion of BRG1 binding sites found in relation to their proximity to a gene.
(E) Gene ontology analysis of differentially bound regions.
(F) Within-subjects differential binding across developmental stages (D0 and D5) showing decreased binding in D0 compared to D5 in
ACTL6Bext*33 cells (pink dots are significant, while blue dots are not). Genes showing a significant difference (FDR-adjusted p values
[Benjamini-Hochberg]% 0.05) in D5 relative to D0 using a GLM as implemented in DESeq2.
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increase in BAF binding at D5 compared to D0 (Figure 6E)
at all sites. These data support the notion that a recessive
ACTL6B mutation leads to increased association of BRG1
to certain areas of the genome.
How does genomic BAF binding affect gene expression
and how might this differ when ACTL6B is mutated? We
performed RNA-seq in affected individual and control cells
(n ¼ 4 independent replicates per subject) at D0 and D5
and looked only at those genes that were detected in the
ChIP-seq analysis. We were interested in those genes that
showed significant changes between D0 and D5 in the
ChIP-seq data and which also showed significant change
in the RNA-seq data between D0 and D5 (within-subjects);
also, we selected those genes that showed RNA-seq differ-
ences between mutant cells and control cells at D5 (Table
S2). We highlight TPPP (Table S4), a microtubule-binding
protein involved in cell process extensions,27,28 and
FSCN1, which has been shown to be involved in neurite
shape and trajectory in prior studies in mice.29 Due to their
biological function and significance levels in our experi-
ments, we chose to use TPPP and FCSN1 expression levels
to assess the external validity of our findings. We note the
prevalence (Table S4) of genes that might be implicated in
sphingolipid biology or myelin processing (SOX8,30
CERK,31 and A4GALT32), consistent with Wu et al.4 who
observed a severe myelination defect in Actl6b KO mice.
WeusedTPPP and FSCN1 expression as outputmarkers to
assess direct versus correlational effects of mutant ACTL6B.
We posed two initial questions to test direct versus correla-
tional effects. First, does the ACTL6B KO show a similar
pattern of expression to ACTL6Bext33 compared to its
isogenic control? Second, do we see the opposite effect in
the UR cells compared to the SR cells? We began by vali-
dating the RNA-seq data, using the same RNA that was
used to make RNA-seq libraries (Figure 7A). Next, we exam-
ined the expression of these genes betweenD0 andD5 time
points in ACTL6B KO cells and their isogenic controls, as
well as in UR and SR cells. SR cells, when compared to UR
cells, showed a significant increase in TPPP and decreased
expression of FSCN1 as NPCs mature from D0 to D5. In
ACTL6B knock-out cells compared to their isogenic con-
trols, we observed significant and opposite effects to that
observed with repaired cells: FSCN1 expression did not
decrease, whileTPPP expression did not increase as the cells
differentiated (Figure 7A). These data provide isogenic evi-
dence that complete loss of ACTL6B and a repair of p.*
427Aspext*33 recapitulate and reverse, respectively,
expression alterations in TPPP and FSCN1 and suggest
that expression changes in these genes are directly caused
by disruption of ACTL6B.
External Validity of TPPP and FSCN1 Expression Levels as
Markers of an ACTL6B Recessive, Loss-of-Function
Disease in Human Neurons using Constructs Derived
from Different ACTL6B Variants
External validity can be provided by KO rescue and by reca-
pitulating expression effects using different mutations in
ACTL6B identified in our cohorts (Figures 7B–7D). If TPPP
and FSCN1 expression levels are markers of loss of function
of ACTL6B, the exogenous re-introduction of ACTL6B on a
KObackground shouldhelp restore their expression toward
levels observed in lineswithwild-typeACTL6B. Further, ex-
pressing mutant ACTL6B to match other variants found in
the recessive cohort should re-establish expression changes
on anACTL6BKObackground.We thereforemadeACTL6B
constructs of two recessive mutations, c.441_443del
(p.Phe147del) and c.1275C>A (p.Cys425*), and the most
prevalent dominant mutation, c.1027G>A, as well as the
WT construct itself. Expressing these variants from trasn-
siently delivered vector on an ACTL6B KO background
may give us an indicationwhether the dominant and reces-
sive variants mediate their effects through the samemolec-
ular pathways and cause similar effects on the expression of
FSCN1 and TPPP. At a D5 time point, cells transfected with
WT ACTL6B showed decreased expression of FSCN1 and
increased expression of TPPP, consistent with what
we observed in the initial KO experiment (Figure 7D),
meaning that the WT construct can rescue the expression
changes observed in ACTL6B KO cells. We observed that
the two recessive variants (c.441_443del and c.1275C>A)
mimicked the effects observed in the recessive p.*427As-
pext*33 variant, while the dominant mutation mimicked
wild-type cells (Figure 7D).
Confirmation of Dendritic Deficits and Gene Expression
Markers using Neurons Derived from ACTL6B Mutant
c.617T>C/c.724C>T
We obtained fibroblasts from individual R9 with com-
pound heterozygous mutations in ACTL6B (c.617T>C
[p.Leu206Pro] and c.724C>T [p.Gln242*]) (Table 1). We
induced the fibroblasts to become iPSCs, differentiated
the iPSCs to D15 neurons, and confirmed the mutant ge-
notype of this line (Figures 8A and 8B). We compared
this ‘‘ACTL6B compound heterozygous mutant’’ line to
healthy control cells differentiated to a day 15 time point
and found a similar decrease of MAP2 staining and
increased nuclei size as compared to the ACTL6B KO and
ACTL6Bext33 lines (Figures 8C and 8D). Assessing the
expression of TPPP and FSCN1 at D5 and D0 time points
in the ACTL6B compound mutant and control lines
also produced results similar to those seen with the
ACTL6Bext33 line, with the ACTL6B compound mutant
showing a lack of increased expression of TPPP as well as
a lack of decreased expression of FSCN1 during differentia-
tion compared to control cells (Figure 8E).
Discussion
These data describe two distinct neurodevelopmental
diseases caused by dominant or recessive mutations
in ACTL6B. This work positions ACTL6B mutations as
causing both a recessive neurological disease characterized
by severe epileptic encephalopathy and a dominant
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intellectual disability syndrome with severe speech and
ambulation deficits.
Previous studies have identified mutations in genes that
code for other subunits of the nBAF and npBAF complexes
that are capable of causing disease through dysregulated
BAF function, collectively called ‘‘Bafopathies.’’33 The
two foremost diseases among the Bafopathies, Coffin-Siris
(CSS) (MIM: 135900) and Nicolaides-Baraitser (NCBRS)
(MIM: 601358) syndrome, show interesting parallels and
differences to the diseases described here.34,35 NCBRS is a
Figure 7. External Validity in Multiple ACTL6B Mutant Models in Human Neurons
(A) TPPP and FSCN1 expression in initial RNA-seq (n R 4) and qPCR (n R 3) data (ACTL6Bext*33 versus control); unrepaired (UR)
ACTL6Bext*33 versus ACTL6Bext*33 successful repair (SR) (n ¼ 6); and ACTL6B KO versus isogenic control cells (n ¼ 5). Results are rep-
resented as mean5 SEM. Student’s t test, *p < 0.05, **p < 0.01, ***p < 0.001.
(B) Experimental plan for generation of multiple human neuronal cell lines expressing various mutant ACTL6B constructs.
(C) Brightfield and GFP images demonstrating high transfection of ACTL6B constructs.
(D) mRNA expression in transfected ACTL6B KONPCs at D5 time points of ACLT6B, TPPP, and FSCN1 (n ¼ 3). Results are represented as
mean5 SEM. Student’s t test, *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 8. Neurons Derived from an Individual with a CompoundMutation in ACTL6B Show a Similar Phenotype to ACTL6Bext33 and
ACTL6B KO Neurons
(A) Schematic showing generation of ACTL6B compound mutant NPCs.
(B) Sanger sequencing traces of ACTL6B compound mutant and control cell line at both identified point mutations in ACTL6B.
(C) Representative TUJ1 and MAP2 staining of control and ACTL6B compound mutation immature forebrain neurons.
(D) Quantification of the surface area of the nucleus in the cell lines shown in (E).
(E) TPPP and FSCN1 expression in ACTL6B compound mutant versus control cells at mitotic (D0) and post-mitotic (D5) time points
(n > 50). Student’s t test, *p < 0.05, **p < 0.01.
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monogenic disease, caused exclusively by mutations in
SMARCA2 (MIM: 600014) that are autosomal dominant,
and CSS is a genetically diverse disease and can be caused
by mutations in ARID1B (MIM: 614556) and a variety of
other genes that play a role in the BAF complex that vary
in their inheritance pattern. Nevertheless, common symp-
toms appear to exist in both these conditions and the dis-
eases described here. Common symptoms reported across
conditions include intellectual disability, developmental
delay, hypotonia, and some form of dysmorphic facial
features.34 Like individuals with recessive mutations in
ACTL6B, individuals with NCBRS also show early-onset
seizures,36 and seizures are also reported in individuals
with CSS, although they are not necessarily early
onset.34,37,38 Individuals with NCBRS also show short pha-
langes,36 as observed in some individuals with dominant
mutations in ACTL6B. However, some of the specific devel-
opmental symptoms observed in these diseases, such as
sparse scalp hair39 or an absent fifth digit,36 do not appear
in individuals with either recessive or dominant mutations
in ACTL6B. This could suggest that while a general disrup-
tion of the BAF complex in a variety of protein subunits
will inevitably lead to intellectual disability and develop-
mental delay, the specific protein subunit that is affected
will determine the presence and nature of dysmorphisms
and epilepsy.
To understand why mutations in ACTL6B cause disease,
we modeled the disease in human NPCs and neurons. We
first confirmed that ACTL6B expression was induced upon
neural cells becoming post-mitotic. We then went on to
make several different cell models in the hope of reducing
variation across experimental variables.Wemade forebrain
progenitor cells from a healthy individual with experimen-
tally induced knock-out of ACTL6B to understand the
effects of complete loss of the gene, in addition to cells
derived from individuals R9 and R3 with an isogenic engi-
neered repaired cell line.
While we cannot precisely determine the mechanism of
the disease that appears to be caused by bi-allelic muta-
tions in ACTL6B, our results do illuminate several key fea-
tures of the etiology of the disease. First, the presence of
BAF53B in the ACTL6Bext33 cell line at D5 eliminates
the possibility that the symptoms are caused by an
absence of BAF53B, as is likely the case in other variants
of BAF53B where NMD is predicted to occur.19 Instead,
it seems plausible that the symptoms are the result of a
loss of function of BAF53B stemming from changes in
the structure of the protein. This hypothesis is supported
by our observations in the ACTL6B KO model, which
shows similar deficits in both MAP2 staining and the
expression of key genes identified in the ACTL6Bext33
that are regulated by BAF. ACTL6B KO cells expressing
the recessive mutations in ACTL6B observed in our reces-
sive cohort fail to rescue aberrant expression of genes,
whereas reintroduction of wild-type ACTL6B does,
strongly suggesting that the phenotype is the result of a
loss of function.
However, how the recessive mutations render BAF53B
non-functional could be due to one of several possibilities.
Perhaps the most intuitive answer is that mutations
disrupt the ability of BAF53B to bind to the BAF complex.
If this fails to occur, this might allow BAF53A to remain
bound in the complex. Given that there are a great many
BAF complexes that dynamically exchange parts to affect
cell differentiation at any one time, a high proportion of
BAF53A in BAF might cause increased affinity of BAF to
the genome in a differentiating cell state compared to
both a proliferating cell state when BAF53B is absent or a
differentiated cell state where BAF53B is present but not
functional and/or when the interaction with the complex
is impaired. The increased presence of BAF53A in the BAF
complex, associated with a more proliferative neuronal
cell state, might also explain the delayed differentiation
we observed in disease cells. Another explanation could
be that recessive mutations do not prevent BAF53B from
binding to the BAF complex, but instead prevent the
various components of the complex from interacting prop-
erly and thus prevent the BAF complex from interacting
with the genome and other proteins in yet unknown
ways. Finally, there is the possibility that recessive muta-
tions do not disrupt BAF complex function significantly
at all, but instead prevent BAF53B from properly interact-
ing with the other complexes such as SRCAP,40 TIP60/
NuA4,19 and INO80.41 Future work will need to look at
how mutant BAF interacts with different proteins.
With respect to the dominant mutation identified in
eight unrelated individuals, we failed to observe the tran-
scription effects we found in the KO, ACTL6B compound
heterozygousmutant, or theACTL6Bext33 cells, suggesting
that dominant and recessive mutations in ACTL6B cause
disease through distinct molecular pathways. This is also
consistent with the observation of different symptoms in
individuals with recessive or dominant mutations in
ACTL6B. Based on the limited molecular information we
have for dominant mutations, there exist many potential
explanations for how a point mutation in ACTL6B might
cause the observed symptoms. Given that these subjects
all have a functioning copy of BAF53B that presumably in-
corporates normally into BAF or other complexes, it is
reasonable to suggest that the ACTL6B dominant muta-
tions identified here may be gain of function. One of the
few clues that we have at this stage of investigation is that
the highly specific nature of the p.Gly343Arg variant sug-
gests that a very precise interaction is being disrupted or
created. Previous work in mice9 has shown that deletion
of the hydrophobic domain of BAF53b results in a domi-
nant-negative form of the protein, causing deficits inmem-
ory, LTP, and gene expression. These deficits were likely
caused by altering the ability BAF53B to interact with other
proteins.9 It is possible that the dominant mutations
observed in this study cause disease by altering the hydro-
phobic domain of BAF53B through a similar mechanism.
Several genes of note may be important targets of the
BAF complex at different developmental stages. FSCN1 is
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one of these and is strongly associated with the formation
of actin, particularly in early neurodevelopment.29,43 The
lack of increase of FSCN1 observed in our models of
ACTL6B dysfunction as cells differentiate may therefore
be the result of neuronal cells remaining in a more prolif-
erative or immature state due to an impairment in the abil-
ity of ACTL6B to transition the BAF complex from promot-
ing genes associated with proliferation to those associated
with neuronal outgrowth.44
The stable expression levels of TPPP observed in models
of ACTL6B dysfunction as NPCs differentiate may reflect
the cytoskeletal changes observed both within our own
models and in the deficits in dendritic spine and synapse
function observed inmouse models of Actl6b KO. It should
also be noted that our ChIP-seq data that initially high-
lighted these genes as being dysregulated are based upon
only BRG1-containing BAF complexes. As BRG1 and
BRM are mutually exclusive components of the BAF com-
plex that are both found in dividing and post-mitotic neu-
ral cells,11 it is possible that the dataset we generated is
only a partial picture of the regions of the genome where
BAF may bind in these cells.
This work brings together extensive clinical samples
and human stem cell modeling to demonstrate that muta-
tions in ACTL6B in human cause severe neurological dis-
orders. Substantially more work will need to be done to
understand the precise mechanisms of how recessive or
dominant mutations in ACTL6B affect incorporation
into the BAF complex and how this incorporation can
alter differential genomic binding and gene expression
patterns.
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